Regulation9 October 2026
An educational overview of how peptides are regulated in the United States, European Union, United Kingdom, and Australia, covering FDA classification, TGA scheduling, EMA frameworks, and MHRA oversight as of 2024-2025.
Collagen Peptides6 October 2026
Collagen peptides and bioactive signalling peptides like BPC-157 or GHK-Cu are fundamentally different molecules with distinct mechanisms, regulatory classifications, and evidence bases. This post explains the key distinctions researchers and clinicians should understand.
Safety2 October 2026
A research-focused overview of what published studies reveal about peptide side effects, contraindications, and the significant gaps in long-term safety data that remain across most peptide classes.
Bioavailability29 September 2026
Bioavailability determines how much of an administered peptide reaches systemic circulation. This overview compares what published research shows about subcutaneous, oral, and nasal delivery routes for peptide compounds.
CJC-129525 September 2026
An educational overview of CJC-1295 and Ipamorelin, two growth hormone secretagogue peptides. This post examines their mechanisms of action, published clinical data, evidence limitations, and current regulatory status.
GHK-Cu22 September 2026
GHK-Cu is a naturally occurring copper-binding tripeptide studied for its potential effects on skin repair, hair growth, and age-related tissue remodelling. Here is what the published research actually shows, and where the evidence gaps remain.
Thymosin Beta-418 September 2026
An evidence-based overview of Thymosin Beta-4's role in wound healing, covering its molecular mechanism, preclinical findings in tissue repair, and the current state of clinical trial evidence in humans.
BPC-15715 September 2026
An evidence-based review of BPC-157 research, covering its origins in gastric juice, proposed mechanisms of action, animal study findings on gut and tissue repair, and the notable absence of published human clinical trials.
Peptide Science11 September 2026
A foundational guide explaining what peptides are, how they are structurally and functionally distinct from proteins, hormones, and small molecules, and why these distinctions matter for research and regulation.
GLP-1 Agonists8 September 2026
An overview of the peptide therapy landscape as of 2025, covering active clinical trials, FDA regulatory pathways, and which peptide candidates are advancing from preclinical research toward approved medicines.
Growth Hormone4 September 2026
Peptide stacking, the practice of using multiple peptides concurrently, is widely discussed but poorly studied. This post examines what the published research actually supports and where significant evidence gaps remain.
Research Methods1 September 2026
A practical guide for researchers and clinicians on evaluating peptide studies, including how to interpret study design hierarchies, allometric dose scaling between species, and what effect sizes actually mean for translational relevance.
Bioavailability18 August 2026
Bioavailability determines how much of an administered peptide reaches systemic circulation. This post examines what the published research shows about subcutaneous, oral, and nasal delivery routes for peptides, including their respective absorption profiles, limitations, and formulation challenges.
GHK-Cu11 August 2026
An evidence-based overview of GHK-Cu, the naturally occurring copper-binding tripeptide studied for its effects on skin repair, hair growth, and age-related gene expression. This post examines what the published research actually shows, including its limitations.
Peptide Fundamentals31 July 2026
A foundational guide to what peptides are, how they are structurally distinct from proteins, hormones, and small molecules, and why these distinctions matter for research and regulation.
BPC-15724 July 2026
Peptide stacking, the practice of combining multiple peptides simultaneously, is widely discussed in online communities but poorly studied in clinical research. This post examines what published evidence exists and where the gaps remain.
Research Methods21 July 2026
A practical guide to critically evaluating peptide studies, covering study design hierarchies, the challenges of translating animal doses to human equivalents, and how to interpret effect sizes in published peptide research.
Peptide Biochemistry23 June 2026
A foundational guide to peptide biochemistry: what defines a peptide, how peptides differ structurally and functionally from proteins, hormones, and small molecules, and why these distinctions matter for research and regulation.
GHK-Cu12 June 2026
An evidence-based review of GHK-Cu research, covering what published studies show about this copper-binding tripeptide's effects on skin, hair follicles, wound healing, and age-related gene expression.
GHK-Cu12 June 2026
An evidence-based review of GHK-Cu research, covering what published studies show about this copper-binding tripeptide's effects on skin, hair follicles, and age-related tissue remodeling, along with key limitations and regulatory context.
GHK-Cu12 June 2026
A research-focused overview of GHK-Cu, the naturally occurring copper-binding tripeptide studied for its effects on skin remodelling, hair follicle cycling, and age-related tissue changes. Evidence quality varies significantly across these domains.
Peptide Science2 June 2026
Peptides, proteins, hormones, and small molecules are often conflated in popular discussion. This guide explains the structural, functional, and regulatory distinctions that matter for researchers and clinicians.
Regulatory Policy29 May 2026
Clinical trials involving peptide-based therapeutics are accelerating across oncology, metabolic disease, and tissue repair, but regulatory frameworks and public communication have not kept pace. The result is a widening information vacuum that grey markets are filling faster than governments.
Growth Hormone Secretagogues26 May 2026
Peptide stacking, the practice of combining multiple peptides concurrently, is widely discussed but poorly studied. This post examines what published research actually supports and where significant evidence gaps remain.
Bioavailability6 May 2026
Bioavailability determines how much of an administered peptide reaches systemic circulation. This post reviews what published research shows about subcutaneous, oral, and nasal delivery routes and the pharmacokinetic trade-offs each presents.
GHK-Cu21 April 2026
GHK-Cu is a naturally occurring copper-binding tripeptide studied for its effects on wound healing, skin remodeling, hair growth, and gene expression associated with aging. This profile reviews the published evidence, its limitations, and current regulatory context.
Peptide Science14 April 2026
An educational overview of how peptides are defined in biochemistry, what distinguishes them from proteins, hormones, and small molecules, and why these distinctions matter for research and regulatory classification.
Pathway Guides10 April 2026
Most peptides in Australia are classified as Schedule 4 (Prescription Only) under the Poisons Standard. Here's what that means for access and legality.
TGA Updates8 April 2026
A comprehensive look at the key peptide scheduling changes the TGA has implemented since mid-2025, including Melanotan II reclassification and compounding framework updates.
Pathway Guides5 April 2026
A step-by-step guide to legally accessing peptide therapies in Australia through prescription pathways, including costs and what to expect.
Market Intelligence28 March 2026
A detailed comparison of grey market peptide sources versus legitimate prescription access, covering quality, legality, cost, and health risks.
Global Regulatory20 March 2026
How the US FDA's Category 1 bulk drug substance list is affecting peptide availability and compounding supply chains in Australia.
Data Reports15 March 2026
Key data points from the Australian peptide market in Q1 2026, covering provider growth, prescribing trends, grey market activity, and enforcement actions.